한글목차

이 보고서는 GSK의 데페모키맙, Tezspire 시장 역학, dexpramipexole과 같은 새로운 치료제와 같은 천식 치료에 대한 최고 KOL의 최신 통찰력, 진화하는 천식 치료의 전망, 최근 임상시험의 주요 결과와 새로운 치료법이 현재 진료에 미치는 영향에 대한 새로운 치료법이 현재 진료에 미치는 영향을 강조하고 있습니다.

보고서 내용

• 향후 3-5년 동안 천식 치료에 영향을 미치는 큰 변화
• 현재 진행 중인 임상시험이 Amgen/AstraZeneca의 항TSLP 단일클론항체 Tezspire의 향후 사용에 어떤 영향을 미칠 수 있는가?
• 항IL5 요법과 Dupixent는 중증 천식에 대한 생물학적 제제로 자리 잡았지만, GSK의 지속형 항IL5제 depemokimab은 얼마나 파괴적일 수 있을까?
• GSK의 Trelegy Ellipta, Novartis의 Enerzair Breezhaler, Chiesi의 Trimbow의 3제 병용요법이 천식에 미치는 영향에 대해 전문가들은 어떻게 보고 있으며, AstraZeneca의 Breztri/Trixeo Aerosphere가 어떤 역할을 할 수 있는가?
• KOL들은 Sanofi의 경구용 BTK 억제제 rilzabrutinib이 천식 치료에 미치는 영향에 대해 어떻게 평가하고 있는가?
• Knopp Biosciences의 경구용 도파민 수용체 작용제 dexramipexole을 천식 환자 치료에 사용하는 EXHALE-2,-3,-4 임상 3상 시험에서 전문가들은 이 경구용 도파민 수용체 작용제의 성공 가능성을 어떻게 평가하고 있는가?

주요 브랜드

영문목차

Explore the latest insights from top KOLs on asthma therapies, including GSK's depemokimab, Tezspire's market dynamics, and novel treatments like dexpramipexole. This report delves into the evolving landscape of asthma treatment, highlighting key findings from recent clinical trials and the impact of emerging therapies on current practice.

Key Questions Answered:

• What will be the major changes to impact the treatment of asthma over the next three to five years?
• How could ongoing clinical trials impact the future use of Amgen/AstraZeneca's anti-TSLP monoclonal antibody Tezspire?
• The anti-IL5 therapies and Dupixent are well-established biologics for severe asthma, but just how disruptive could GSK's long-acting anti-IL5 agent depemokimab be?
• How do experts view the role of fixed-dose triple-combination therapies (GSK's Trelegy Ellipta, Novartis' Enerzair Breezhaler and Chiesi's Trimbow) in asthma, and could AstraZeneca's Breztri/Trixeo Aerosphere find a role?
• How do the KOLs assess the prospects for Sanofi's oral BTK inhibitor rilzabrutinib to impact asthma treatment practice?
• With the Phase III EXHALE-2, -3 and -4 trials evaluating Knopp Biosciences' dexpramipexole in the treatment of patients with asthma, how do experts weigh up this oral dopamine receptor agonist's prospects for success?

Key Brands:

Partial List of Participating Experts:

• Professor of Pediatrics, Allergy/Immunology/Pulmonary Medicine, Scientific Director of the Center for Clinical and Translational Research, Vanderbilt University Medical Center, USA
• Professor of Medicine (Pulmonary, Critical Care and Sleep Medicine), Yale School of Medicine, USA
• Clinical Professor of Medicine, University of Medicine and Dentistry of New Jersey - Rutgers, Director of Clinical Research at Pulmonary and Allergy Associates, USA
• Professor of Thoracic Medicine and Head of Respiratory Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, Senior Research Investigator at Imperial College, UK
• Head of Pulmonology, Consultant and Professor of Respiratory Medicine at Arnaud de Villeneuve Hospital/University of Montpellier, France
• Head of Department of Allergy, La Paz University Hospital, IdiPAZ, CIBER of Respiratory Diseases (CIBERES), Universidad Autenoma de Madrid, Spain

Methodology

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.